




























In a hostile environment rife with microbial invaders, 
mammals respond to wounding and tissue injury with a 
vigorous inflammatory response coupled to the rapid 
synthesis and deposition of extracellular matrix (ECM), 
thereby maintaining tissue integrity and providing 
defense against microbes while the wounded tissue is 
being repaired and remodeled. In virtually all 
mammalian organ systems, wound healing occurs 
similarly in three overlapping but distinct phases: 
inflammation, ECM deposition and tissue formation, 
and tissue remodeling [18,35,37]. Each of these steps 
must be tightly regulated for optimal wound healing. 
However, excessive ECM deposition may occur in 
wound repair, particularly in association with chronic 
injury and inflammation [15,38,43]. When excessive, 
non-functional ECM replaces parenchyma, the resulting 
fibrosis, scarring, and loss of tissue function may lead to 
deleterious consequences. For example, fibrotic scarring 
in the liver due to viral infections, in the lung from 
obstructive pulmonary disease, and in the heart 
following myocardial infractions can lead to organ 
failure and death. These types of dysfunctional wound 
healing adversely affect a large number of people 































The principal cell type that contributes to the synthesis 
and deposition of ECM in healing wounds is the 
myofibroblast, which expresses α-smooth muscle actin 
and promotes wound contraction [43]. Myofibroblasts 
can be derived from a variety of sources, including 
differentiation of activated resident fibroblasts and 
recruited fibrocytes, and epithelial- and endothelial-
mesenchymal transitions of epithelial and endothelial 
cells, respectively [14,43]. Whereas activated myo-
fibroblasts proliferate and initially promote wound 
repair by producing ECM components, fibrosis may 
result when wound healing becomes chronic or if the 
ECM producing activity of myofibroblasts continues 
unchecked. However, the mechanism that keeps ECM 
production in balance with wound healing is poorly 
understood. Here we discuss the evidence indicating 
that myofibroblasts are driven into senescence at later 
stages of wound healing, thereby converting these 
ECM-producing cells into ECM-degrading cells, thus 
imposing a self-limiting control on fibrogenesis. In skin 
wound healing, myofibroblast senescence is triggered 
by the dynamically expressed matricellular protein 






















myofibroblast  senescence  is  a  programmed  wound  healing  response  that  functions  as  a  self‐limiting  mechanism  for
fibrogenesis, and this process may be regulated by the ECM microenvironment through the expression of CCN1/CYR61.   
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First recognized in human fibroblasts experiencing 
replicative exhaustion in culture [19,20], cellular 
senescence is an essentially irreversible form of cell-
cycle arrest that can be triggered by a variety of cellular 
damage or stress, including DNA damage, chromatin 
disruption, oncogene activation, oxidative stress, and 
telomere dysfunction [4,10]. Senescent cells remain 
viable and metabolically active, but are refractory to 
mitogenic stimulation. Another important feature of 
senescent cells is the expression of the senescence-
associated secretory phenotype (SASP) or the 
senescence messaging secretome (SMS)[4,28,45], 
characterized by the increased expression of 
inflammatory cytokines/chemokines (e.g., IL1, IL6, 
IL8, MCP2, MCP4, MIP-1a, MIP-3a) and ECM 
degrading enzymes (e.g., matrix metalloproteinases 
[MMPs]), and downregulated expression of ECM 
components (e.g., collagen) [12,36]. Compelling 
evidence has established cellular senescence as an 
important mechanism of tumor suppression, which 
functions by blocking the proliferation of damaged cells 
that may be at risk of oncogenic transformation 
[3,9,13,29]. Paradoxically, the expression of 
SASP/SMS by senescent cells can also facilitate cancer 
progression by modifying the tissue microenvironment 
[11]. Therefore, senescent cells may have diverse and 
context-dependent effects on tissue pathologies. 
Although senescent cells have been found in various 
noncancerous pathologies and aging-related diseases, 























investigated [16,31].  
 
Two recent studies have shown that senescent 
myofibroblasts accumulate as part of the normal process 
of tissue repair, and function to limit the extent of 
fibrogenesis associated with wound healing [22,26]. 
Upon damage in the liver, activated hepatic stellate cells 
are the primary source of myofibroblasts, which 
proliferate and produce matrix proteins to support 
hepatocyte proliferation and organ repair [2,32]. In 
chronic liver injuries, these cells are also responsible for 
excessive ECM production, leading to fibrosis and 
eventually cirrhosis. Krizhanovsky et al. showed that in 
mice subjected to repeated injections of carbon 
tetrachloride (CCl4), a protocol that induces liver 
damage and fibrosis, some of the ECM producing 
myofibroblasts eventually become senescent and 
express the SASP/SMS [26]. These senescent cells 
function to limit fibrosis in several ways: 1. they cease 
to proliferate, reducing the number of ECM producing 
cells; 2. they curtail the synthesis and promote the 
degradation of matrix components through the 
expression of SASP/SMS; and 3. they are eventually 
cleared by natural killer cells, thereby removing the 
myofibroblasts and accelerating the resolution of 
fibrogenesis and wound healing [26,44]. The expression 
of inflammatory cytokines as part of the SASP/SMS 
may also promote immune surveillance at the wound 
site [25,26]. Consistent with these interpretations, mice 
that are genetically defective for p53 and/or p16
INK4a, 
which are critical for mediating senescence, suffer 
exacerbated fibrosis and delayed resolution of fibrosis 
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operate in excisional cutaneous wound healing, which 
involves a tissue and mode of injury distinct from CCl4-
induced liver damage [22]. During skin wound healing, 
recruited fibroblasts and differentiated myofibroblasts 
proliferate and deposit ECM to form the granulation 
tissue. Myofibroblasts are driven into senescence at 
later stages of wound healing, whereupon they cease to 
proliferate and upregulate the expression of matrix 
degrading enzymes (MMP2, MMP3, and MMP9) 
concomitant with downregulation of collagen and TGF-
β, thereby exerting an anti-fibrotic effect [22]. Hence, 
the control of fibrogenesis during wound healing is 
efficient and parsimonious – the very cells that 
synthesize ECM in wound healing, the myofibroblasts, 
are themselves converted into matrix-degrading 
senescent cells to produce a self-limiting effect (Figure 
1). These senescent cells may also promote tissue 
remodeling and clearance of the myofibroblasts during 
wound maturation. It is interesting to note that 
senescent cells are not required for wound healing per 
se, since healing occurs in mutant mice deficient in 
senescent cell accumulation [22,26]. 
 
CCN1 controls cellular senescence in cutaneous 
wound healing  
 
Whereas the factors that trigger senescence of activated 
stellate cells in CCl4-induced liver injury are currently 
unknown, senescence in cutaneous wounds is controlled 
by CCN1 (also known as CYR61), a matricellular 
protein dynamically expressed at sites of inflammation 
and wound healing [7]. Purified CCN1 protein can 
directly induce fibroblast senescence, both as a soluble 
factor and as an immobilized cell adhesion substrate 
[22]. Mechanistically, CCN1 induces fibroblast 
senescence through its direct binding to integrin α6β1 
and cell surface heparan sulfate proteoglycans (HSPGs), 
thereby activating RAC1 and the RAC1-dependent 
NADPH oxidase 1 to trigger a robust and sustained 
accumulation of reactive oxygen species (ROS). 
Consequently, CCN1 induces DNA damage response 
and p53 activation, and triggers the ROS-dependent 
activation of p38 MAPK and ERK, which in turn 
activate the p16
INK4a/pRb pathway to induce senescence 
(Figure 2). Both p53 and p16
INK4a/pRb pathways 
contribute to CCN1-induced senescence [4,10]. Cell 
adhesion to CCN1 induces a much higher and more 
sustained level of ROS than cell adhesion to other ECM 
proteins such as collagen, fibronectin, and laminin, 
which do not induce senescence. The accumulation of a 
substantial level of ROS sustained for at least 10 hours 
appears necessary for efficient induction of senescence 
in fibroblasts [22]. A CCN1 mutant protein (DM) 
disrupted in its α6β1-HSPGs binding sites is unable to 
induce senescence or the SASP. Consistently, knockin 
mice in which the dm allele replaces the genomic Ccn1 
locus (Ccn1
dm/dm) lack senescent cells in the granulation 
tissue and suffer exacerbated fibrosis during cutaneous 
wound healing [22]. Topical application of purified 
CCN1 protein to cutaneous wounds reverses these 
defects, further establishing the critical role of CCN1 in 





































Future questions and prospects 
 
As the role of cellular senescence in wound healing and 
tissue repair is only beginning to be appreciated, many 
questions still remain. First, how broadly is cellular 
senescence invoked as a mechanism of fibrosis control? 
The observation that cellular senescence operates in 
both excisional skin wounds and toxin-induced liver 
injury, two different modes of wounding in disparate 
organ systems, suggests that senescence may be part of 
a general, programmed mechanism of fibrosis control in 
Figure  2.  A  mechanistic  model  for  CCN1‐induced
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CCN1 functions to control senescence in contexts other 
than cutaneous wound healing is not yet known, 
although its high expression at many sites of 
inflammation and tissue injury suggests a role in 
disparate models of wound healing [7].  
 
In addition to CCN1, other factors expressed in the 
wound microenvironment may also promote 
senescence. For example, overexpression of the 
plasminogen activator inhibitor-1 (PAI-1) is sufficient 
to drive fibroblasts into senescence in vitro [24]. PAI-1 
knockout mice showed accelerated wound closure with 
diffused and unorganized collagen deposition, although 
whether PAI-1 controls senescence in healing wounds is 
currently unknown [6]. Interestingly, CCN1 can 
upregulate PAI-1, possibly through the activation of p53 
[8]. Additionally, several secreted proteins such as 
insulin-like growth factor binding proteins (IGFBPs), 
cytokines such as IL6, and ligands of the chemokine 
receptor CXCR2 have been shown to mediate or 
reinforce senescence [1,23,27,34,41,42]. Some of these 
secreted factors are also involved in wound healing 
[17,21], although their potential role in myofibroblast 
senescence or fibrosis control remains to be explored. 
 
Further investigation will be required to assess the role 
of cellular senescence in wound healing-related 
pathologies in humans. Senescent cells have been 
isolated from chronic and non-healing wounds such as 
pressure sores, diabetic ulcers, and venous ulcers, and 
may contribute to wound chronicity [39,40]. It is 
possible to postulate that excessive accumulation of 
senescent cells might have arisen from the enhanced 
expression of factors controlling senescence, such as 
CCN1 or PAI-1, as a measure to control fibrosis in 
chronic injury. Assessment of whether these senescence 
inducing factors are deregulated in chronic wounds may 
shed light on this issue. Senescent cells have also been 
found in various human pathologies associated with 
inflammation or injury repair, including atherosclerotic 
plaques [30], osteroarthritis [33], and benign prostatic 
hyperplasia [5]. Determining whether cellular 
senescence is invoked as a mechanism for fibrotic 
control in these contexts will be of interest. Further 
studies that identify the critical regulators of senescence 
in these pathologies, for which CCN1 is a candidate, 
may underscore potential signaling pathways for 
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